Dr. Corbeil received his bachelor of science degree, with a concentration in biochemistry, and a master of science, with a concentration in experimental medicine, from Universit Laval. He obtained his PhD from the University of New South Wales in Sydney, Australia , where he studied HIV-associated Kaposi’s sarcoma. Dr. Corbeil then moved to the University of California in San Diego for postdoctoral training in infectious diseases. He created the UCSD Center for AIDS Research Genomics core laboratory and achieved associate professor status, before moving back to Quebec City. Dr. Corbeil currently focuses on using the latest techniques in bioinformatics and machine learning to assist and facilitate the processes of diagnosis and prognosis determination and to optimize response to treatment. Modern genomic techniques generate a deluge of data that needs to be interpreted using novel bioinformatic approaches. Dr. Corbeil uses state-of-the-art instrumentation and big data analytics to facilitate the interpretation of complex phenotypic data. His research includes investigating how infectious microorganisms interact with their hosts, examining the effects of antibiotics on our microbial flora, exploring how to design small molecules and drugs to interfere with specific microbial functions and integrating omic data in cancer research. Dr. Corbeil operates at the interface of computer and omic sciences. Dr. Jacques Corbeil is currently the Canada Research Chair in Medical Genomics and serves as an advisor to a number of biotechnology oriented companies.
Dr. Tony Hunter, a professor in the Molecular and Cell Biology Laboratory, studies how cells regulate their growth and division, and how mutations in genes that regulate growth lead to cancer. Hunter received his BA and PhD from the University of Cambridge in England, before coming over to Salk as a Postdoctoral Fellow. His lab has made significant contributions in the area of signal transduction, how signals that stimulate or rein in growth are routed within a cell. In 1979, his lab discovered that phosphate can be attached to tyrosine residues in proteins. This seminal discovery opened the door to the study of tyrosine kinases and their role in signal transduction, and in cell growth and development, as well as to their role in cancer and other human diseases. This knowledge already has resulted in a new approach to cancer treatment. Cancer drugs, such as leukemia Gleevec, have been designed based on Hunter’s discoveries. His efforts have aimed at elucidating how protein phosphorylation, ubiquitination, and SUMOylation events are used to regulate cell proliferation and growth control, and cell cycle checkpoint activation in response to DNA damage. His work has highlighted the importance of crosstalk and feedback loops in the PI-3 kinase-Akt-mTOR cell growth pathway, has elucidated mechanisms of activation of the ATM protein kinase in response to double strand DNA breaks, and has identified a role for the ERK MAP kinase pathway in the motility of early breast carcinoma cells. In 2018 Hunter received the Tang Prize in Biopharmaceutical Science and the Pezcoller–AACR International Award for Extraordinary Achievement in Cancer Research.
Nasoff received his PhD in microbial genetics from the University of Maryland, which was followed by Postdoctoral training in organic synthesis at the University of Colorado. Nasoff brings to the board 35 years of industry experience, and currently serves as the Chief Scientific Officer of Biologics at COI Pharmaceuticals. Previously Nasoff served as the director of Biologics at GNF and worked closely with Novartis on the development of therapeutic antibodies. The goal of the GNF antibody program was to advance biotherapeutics into the Novartis drug discovery pipeline. Nasoff has authored over 50 patents and more than 30 publications.